NCT02889328View on ClinicalTrials.gov

Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

August 9, 2017

Study Completion Date

January 31, 2018

Conditions
Gastrointestinal Stromal Tumors (GISTs)
Interventions
DRUG

Regorafenib

Regorafenib 100mg continuous dosing arm

Trial Locations (1)

138-736

Asan Medical Center, University of Ulsan College of Medicine, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT02889328 - Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs | Biotech Hunter | Biotech Hunter